S-1: BullFrog AI Files S-1 for $10M Lincoln Park Stock Offering

BullFrog AI Holdings, Inc. filed an S-1 registration statement for the resale of up to 5,000,000 common shares by Lincoln Park Capital Fund, LLC, and to register shares for a potential $10 million capital raise.

Summary

• The company filed an S-1 registration statement for the resale of up to 5,000,000 shares of common stock by Lincoln Park Capital Fund, LLC.
• The company may receive up to $10,000,000 in aggregate gross proceeds from sales of common stock to Lincoln Park under a Purchase Agreement over a 36-month period.
• BullFrog AI focuses on advanced Artificial Intelligence / Machine Learning (AI/ML) analysis of complex data for drug development, utilizing its proprietary bfLEAP platform.
• Key collaborations include Eleison Pharmaceuticals Inc. for clinical trial optimization and Sygnature Discovery for drug discovery services.
• The company holds exclusive worldwide license agreements with Johns Hopkins University for a cancer drug targeting glioblastoma and pancreatic cancer, and with George Washington University for a cancer drug targeting hepatocellular carcinoma.
• A strategic data and commercialization agreement with the Lieber Institute for Brain Development (LIBD) aims to analyze large postmortem brain data sets for drug target discovery.
• The company received a Nasdaq notice on August 21, 2025, indicating non-compliance with the minimum $2,500,000 stockholders' equity requirement, reporting $2,188,110 as of June 30, 2025.
• A special meeting of stockholders is scheduled for October 22, 2025, to vote on a reverse stock split at a ratio of not less than 1-to-2 and not more than 1-to-15.
• The independent registered public accounting firm expressed substantial doubt about the company's ability to continue as a going concern in its audit report for the fiscal year ended December 31, 2024.
• As of June 30, 2025, the company had a cash balance of approximately $2.6 million, including $0.1 million restricted cash.
• From April 25, 2025, through October 6, 2025, the company sold 755,116 shares through its At-The-Market (ATM) program for aggregate net proceeds of $1.15 million.

Sentiment

Score: 3

Explanation: While the company has secured a potential $10 million capital commitment and made progress in collaborations and technology development, the immediate concerns regarding Nasdaq non-compliance due to insufficient stockholders' equity and the auditor's 'going concern' warning present significant financial instability and operational risks. The potential for substantial dilution from the Lincoln Park agreement and the proposed reverse stock split further contribute to a cautious outlook.

Positives

• Secured a potential $10 million capital commitment from Lincoln Park Capital Fund, LLC, providing a source of future funding.
• Established significant collaborations with Eleison Pharmaceuticals (Phase III oncology company) and Sygnature Discovery (drug discovery CRO) to leverage its AI/ML platform.
• Holds exclusive worldwide license agreements for promising cancer drug assets from Johns Hopkins University and George Washington University.
• Entered into a strategic data and commercialization agreement with the Lieber Institute for Brain Development, gaining access to extensive brain data sets for drug target discovery.
• Proprietary AI/ML platform (bfLEAP) was created from technology originally developed at The Johns Hopkins University Applied Physics Laboratory and is continuously evolving.
• Completed its first commercial service contract with a leading rare disease non-profit organization in 2023.

Negatives

• Received a Nasdaq deficiency notice on August 21, 2025, for non-compliance with the minimum $2,500,000 stockholders' equity requirement, reporting only $2,188,110 as of June 30, 2025.
• The independent registered public accounting firm expressed 'substantial doubt about our ability to continue as a going concern' in its audit report for the fiscal year ended December 31, 2024, due to continued net losses and negative cash flows.
• The potential sale of up to 5,000,000 shares to Lincoln Park will have a dilutive impact on existing stockholders.
• The company has a history of operating losses since inception and expects to incur additional near-term losses.
• The company's ability to access the full $10 million under the Purchase Agreement is not guaranteed and is subject to market conditions, beneficial ownership caps, and stockholder approval for the Exchange Cap.
• Risk of delisting from Nasdaq if compliance requirements, including the minimum bid price of $1.00 per share, are not met.

Risks

• Management has broad discretion in the use of existing cash and proceeds from the offering and may not use them effectively.
• The sale or availability for sale of shares may depress the common stock price, dilute existing stockholders, and encourage short sales by third parties.
• Future equity offerings could lead to further dilution for current investors.
• Future sales or issuances of common stock in public markets, or the perception of such sales, could depress the trading price.
• The company does not currently intend to pay dividends, meaning investor return depends solely on stock price appreciation.
• Investors who buy shares at different times will likely pay different prices, and Lincoln Park's sales could cause the stock price to decline.
• The company may not have access to the full $10 million available under the Purchase Agreement with Lincoln Park due to various limitations.
• Additional financing may be required to sustain operations, and the terms of subsequent financings may adversely impact stockholders.
• Inability to maintain listing on Nasdaq or any other stock exchange could adversely affect stock price, liquidity, and ability to obtain financing.
• The independent registered public accounting firm has included an explanatory paragraph relating to the company's ability to continue as a going concern.

Future Outlook

The company aims to utilize its bfLEAP AI/ML platform for precision medicine in drug development with biopharmaceutical collaborators and internal clinical programs, believing it will lead to faster, less expensive drug approvals. It plans to continuously evolve and improve bfLEAP, secure rights to other proprietary data sets, and potentially acquire rights to failed therapeutic candidates for drug rescue, including conducting late-stage clinical trials. The company is actively developing new intellectual property and expanding staff for drug target discovery and analytical services, while also launching initiatives targeting large public health data sources.

Management Comments

• Our objective is to utilize bfLEAP, our AI/ML platform, with a precision medicine approach toward drug development with biopharmaceutical collaborators, as well as our own internal clinical development programs.
• We believe the bfLEAP platform is ideally suited for evaluating pre-clinical and clinical trial data generated in translational research and clinical trial settings in order to lead to faster, less expensive drug approvals.
• We intend to continue to evolve and improve bfLEAP, either in-house or with development partners like JHU-APL.
• We plan to leverage our proprietary AI/ML platform developed over several years at one of the top innovation institutions in the world which has already been successfully applied in multiple sectors.
• We intend to secure the rights to other proprietary data sets and repeat this strategy.
• Additionally, we intend to gain access to later-stage clinical assets through partnerships or the acquisition of rights to failed therapeutic candidates for drug rescue.
• The Company intends to take all reasonable measures available to regain compliance with the Nasdaq listing rules and remain listed on Nasdaq.

Industry Context

The filing highlights BullFrog AI's strategy to leverage advanced Artificial Intelligence and Machine Learning (AI/ML) in drug discovery and development, aligning with a broader industry trend towards precision medicine and data-driven approaches to accelerate drug approvals and reduce costs. Collaborations with biopharmaceutical companies, research institutions like Johns Hopkins and George Washington Universities, and data repositories such as the Lieber Institute for Brain Development, demonstrate an industry shift towards external partnerships and specialized AI platforms to enhance R&D efficiency and identify novel therapeutic targets, particularly in oncology and neurological disorders. The focus on 'drug rescue' for previously failed therapeutic candidates also reflects an industry effort to maximize value from existing research data.

Corporate Governance

Related Party Transactions

• In early April 2022, the company received $100,000 from the sale of a Convertible Bridge Note and Warrants to a related party.

Stakeholder Impact

• Shareholders face significant dilution from the potential sale of up to 5,000,000 shares to Lincoln Park, and risk of further dilution from future equity offerings.
• Shareholders face the risk of delisting from Nasdaq, which could materially reduce liquidity and the market price of common stock.
• The proposed reverse stock split, while intended to address Nasdaq compliance, could also impact share value and investor perception.
• Employees and consultants benefited from IPO proceeds used to retire accrued debts.

Next Steps

• Seek stockholder approval on October 22, 2025, for a reverse stock split (ratio 1-to-2 to 1-to-15).
• Seek stockholder approval on October 22, 2025, to issue shares to Lincoln Park in excess of the 19.99% Exchange Cap under Nasdaq rules.
• Submit a plan to Nasdaq within 45 calendar days of August 21, 2025, to regain compliance with the Stockholder Equity Requirement.
• Continue to evolve and improve the bfLEAP AI/ML platform, potentially with development partners.
• Secure rights to other proprietary data sets and repeat the strategy of analyzing data for market opportunities.
• Potentially gain access to later-stage clinical assets through partnerships or acquisitions for drug rescue.
• Conduct late-stage clinical trials in certain circumstances to rescue previously failed therapeutic assets.
• Transition accounting and financial reporting systems and processes to enhance the internal control environment.

Key Dates

Recommendation

The company faces critical challenges, including a Nasdaq non-compliance notice for insufficient stockholders' equity and an explicit 'going concern' warning from its auditors. While a potential $10 million capital raise from Lincoln Park is positive, it comes with significant dilution risks and is contingent on market conditions and stockholder approval. The proposed reverse stock split is a reactive measure to maintain Nasdaq listing, not a sign of fundamental strength. The combination of financial instability, regulatory non-compliance, and substantial dilution risks makes the stock a high-risk investment with a negative outlook.

Keywords

BullFrog AI, BFRG, SEC Filing, S-1, Stock Offering, Capital Raise, AI/ML, Drug Development, Biopharma, Nasdaq Compliance, Going Concern, Dilution, Lincoln Park Capital, Biotechnology, Artificial Intelligence, Machine Learning, Healthcare Technology